CD70 is a protein found on the surface of certain immune cells that, in healthy people, helps activated T cells multiply and fight infections. It belongs to the same family of signaling molecules as tumor necrosis factor (TNF), and its normal job is to bind a partner receptor called CD27 on T cells, delivering a “go” signal that ramps up the immune response. The problem is that many cancers hijack this protein, plastering it across tumor cells in abnormally high amounts and using it to suppress the very immune defenses that should be attacking them. That dual identity makes CD70 an appealing drug target: it sits on the outside of cancer cells where drugs can reach it, it is overexpressed in tumors but tightly controlled in normal tissue, and blocking it can potentially re-awaken immune responses that the tumor has shut down.
What CD70 Does in a Healthy Immune System
CD70 was identified in the early 1990s as the binding partner, or ligand, for the CD27 receptor on T cells. Researchers confirmed that it is a type II transmembrane glycoprotein, meaning it is anchored in the cell membrane with a portion sticking out into the surrounding environment.1PubMed. CD70 represents the human ligand for CD27 It was cloned from activated lymphocytes and shown to stimulate T cell proliferation in laboratory assays, establishing its role as a costimulatory molecule.2Oxford Academic (The Journal of Immunology). The cloning of CD70 and its identification as the ligand for CD27
Under normal circumstances, CD70 appears only briefly on the surface of activated T cells, B cells, and dendritic cells. When a T cell encounters a threat and gets activated, nearby immune cells temporarily display CD70. That CD70 plugs into CD27 on the T cell’s surface, delivering a costimulatory signal that drives the T cell to expand its numbers and mature into an effective killer or helper cell. Once the threat is handled, CD70 expression shuts back down. This tight on-off regulation is critical. Studies in mice showed that when CD70 was artificially kept on all the time in B cells, the animals ended up with vastly increased numbers of effector T cells and a depleted B cell population, illustrating the damage that uncontrolled CD70 signaling can do.3Immunity. Constitutive CD70 Expression on B Cells Results in Increased Numbers of Effector T Cells and Decreased B Cell Numbers in Vivo
How Cancer Cells Co-opt CD70
In a range of cancers, the careful regulation of CD70 breaks down. Tumor cells begin producing the protein at high and persistent levels, turning what should be a brief immune activation signal into a chronic presence within the tumor environment.4Clinical and Translational Discovery. Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities This happens through several converging forces. Inflammatory signals inside the tumor, low-oxygen conditions (hypoxia), and certain mutations can all drive CD70 production upward. In clear cell renal cell carcinoma, for instance, loss of the VHL gene stabilizes a protein called HIF-2α, which in turn pushes CD70 expression higher, linking it to more aggressive disease.
The consequences are counterintuitive. You might expect that more of a “go” signal on the tumor would help the immune system attack it, but chronic CD70 signaling does the opposite. Persistent engagement of CD27 on T cells leads to T cell exhaustion, a state where the T cells become dysfunctional and can no longer mount an effective response. At the same time, CD70 on tumor cells promotes the expansion of regulatory T cells (Tregs), which are immune cells whose job is to suppress immune responses. Research on nasopharyngeal carcinoma showed that tumor cells used CD70-CD27 interaction to boost Treg development and suppressive activity, effectively building a shield of immune-dampening cells around the tumor.5Nature Communications. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction CD70-expressing tumors can also activate myeloid-derived suppressor cells, further deepening the immunosuppressive environment.
There is an additional mechanism at play. CD70 on tumor cells can directly damage the B cells and T cells that infiltrate the tumor, inducing cytotoxic effects on those lymphocytes and helping the cancer escape immune surveillance.6PubMed Central. CD70 expression patterns in renal cell carcinoma So the same molecule that normally empowers the immune system becomes a weapon the tumor wields against it.
Which Cancers Express CD70
CD70 overexpression has been documented across a surprisingly wide array of cancer types, both blood cancers and solid tumors. The cancers where CD70 shows up most prominently include renal cell carcinoma (especially clear cell and sarcomatoid subtypes), glioblastoma, and acute myeloid leukemia.4Clinical and Translational Discovery. Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities Non-Hodgkin lymphoma, T-cell malignancies, and nasopharyngeal carcinoma are also on the list.
In renal cell carcinoma specifically, a study comparing tumor tissue to normal kidney tissue found that CD70 expression was on average roughly twice as high in tumors. Clear cell and sarcomatoid subtypes showed the strongest overexpression, while some papillary tumors and oncocytomas had variable levels.6PubMed Central. CD70 expression patterns in renal cell carcinoma A pan-cancer analysis confirmed elevated CD70 levels in several cancer types, with clear cell renal cell carcinoma standing out as a particularly strong candidate for CD70-targeted therapies.7PubMed. Comprehensive pan-cancer analysis reveals CD70 as a promising therapeutic target and biomarker in clear cell renal cell carcinoma
The breadth of this expression pattern is one of the reasons CD70 has attracted so much interest as a drug target. A molecule that appears across many cancer types but stays largely quiet in healthy tissue presents an unusually clean opportunity for targeted therapy. Healthy tissues rarely express CD70 in significant amounts, reducing the risk that a drug aimed at CD70 will cause collateral damage.
CD70 as a Prognostic Marker
Beyond being a drug target, CD70 levels can also tell you something about how a patient’s cancer is likely to behave. In small cell lung cancer, patients with high CD70 expression in their tumors had significantly shorter overall survival compared to those with low expression. The hazard ratio was roughly 1.8, meaning the high-CD70 group faced about 80% greater risk of death, and this held up even when looking only at early-stage patients.8PubMed Central. Expression of costimulatory molecule CD70 is prognostic in small cell lung cancer In clear cell renal cell carcinoma, elevated CD70 similarly correlated with poor prognosis.7PubMed. Comprehensive pan-cancer analysis reveals CD70 as a promising therapeutic target and biomarker in clear cell renal cell carcinoma
This pattern makes intuitive sense given what CD70 does in a tumor: higher expression means a more immunosuppressive microenvironment, more exhausted T cells, more Tregs, and ultimately a cancer that is better at hiding from the immune system. It also means that measuring CD70 could help identify the patients most likely to benefit from CD70-targeted treatments.
Therapeutic Approaches Targeting CD70
Researchers have attacked CD70 from several different angles, and the diversity of approaches reflects both the attractiveness of the target and the challenges each strategy faces.
Naked Antibodies
The simplest concept is a monoclonal antibody that binds CD70 on the tumor cell surface and recruits the patient’s own immune cells to destroy it. An engineered anti-CD70 antibody with a human IgG1 backbone was shown to trigger antibody-dependent cellular cytotoxicity (where natural killer cells attack the tagged tumor cell), complement-dependent cytotoxicity (where blood proteins punch holes in the tumor cell), and phagocytosis (where macrophages engulf it). In mice bearing human lymphoma tumors, this antibody significantly extended survival, and the effect depended on the activity of the animals’ own immune effector cells.9Blood. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
A next-generation antibody called ARGX-110 (later known as cusatuzumab) was engineered to have even stronger tumor-killing ability. It eliminated tumor cells with greater efficiency than a standard version and additionally acted as a kind of immune checkpoint blocker, since binding CD70 can disrupt the immunosuppressive signaling that the tumor depends on.10PubMed Central. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade Another antibody, SGN-70, showed similar Fc-dependent killing of CD70-positive tumor cells in preclinical work.11Clinical Cancer Research. Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
Antibody-Drug Conjugates
An antibody-drug conjugate, or ADC, takes the antibody concept a step further. Instead of relying solely on the immune system to destroy the tagged cell, the antibody carries a potent cell-killing chemical payload. When the antibody binds CD70 and gets pulled inside the cancer cell, it releases the toxin directly where it can do the most damage. Researchers created an anti-CD70 antibody conjugated to a drug called MMAF (monomethylauristatin F) and tested different antibody backbone variants. All versions bound to CD70-positive cells with high affinity, around one nanomole per liter, and drug attachment did not weaken that binding.12AACR Journals. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index This approach led to the clinical development of SGN-75, which was tested in a phase I trial in patients with relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
CAR-T Cell Therapy
CAR-T therapy involves taking a patient’s (or a donor’s) T cells, engineering them to recognize a specific target on cancer cells, and infusing them back. CD70-targeted CAR-T cells have been developed, but they face a unique obstacle: because T cells themselves can express CD70 when activated, the engineered CAR-T cells sometimes attack each other, a problem called fratricide.13International Immunopharmacology. Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC Researchers have worked around this by using gene editing to knock out CD70 on the CAR-T cells themselves, and a CRISPR-engineered allogeneic (donor-derived) CAR-T product called CTX130 has entered clinical trials for T-cell malignancies. In a phase I trial, the therapy showed activity, though the most common severe side effects were low blood counts: about a third of patients experienced severe neutropenia and roughly a quarter had severe anemia.14PubMed Central. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM)
Bispecific T-Cell Engagers
Bispecific molecules are designed to grab a T cell with one arm and a tumor cell with the other, physically bridging them so the T cell can kill. An anti-CD70 bispecific T-cell engager with an extended half-life was characterized in primate studies, which revealed a tricky finding: the molecule could be active even in tissues with very low CD70 expression, and CD70 could be upregulated under stress, potentially causing on-target toxicity in unexpected places.15PubMed. Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys This is a useful reminder that CD70’s low expression in normal tissue is not the same as zero expression, and drugs that are exceptionally potent at engaging T cells can cause problems even at low target densities.
Safety Considerations
Because CD70 is present at low levels on some healthy immune cells, any drug targeting it will inevitably affect those cells to some degree. The phase I trial of the ADC SGN-75 found that treated patients commonly experienced fatigue, dry eye, nausea, and low platelet counts. The drug also depleted CD70-positive peripheral blood lymphocytes, which was essentially proof that the drug was hitting its target, but it also meant patients lost a subset of their normal immune cells.16PubMed. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
For the CAR-T product CTX130, the side-effect profile looked more like what you would expect from any CAR-T therapy: primarily low blood counts (neutropenia, anemia, thrombocytopenia) as the dominant severe toxicities.14PubMed Central. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM) What makes these toxicities more tolerable than they might sound is that they are generally manageable with supportive care, and the patients receiving these treatments have cancers that have already resisted other therapies. The calculus of acceptable side effects looks very different when the alternative is untreated relapsed cancer.
Combining CD70 Blockade with Checkpoint Inhibitors
One of the more exciting avenues in CD70 research is combining it with PD-1 checkpoint inhibitors, the drugs that have already transformed treatment for many cancers. The rationale is elegant: anti-CD70 treatment reduces the Treg population that suppresses immune responses, while anti-PD-1 treatment directly reinvigorates exhausted T cells by blocking a separate brake on immunity. By hitting both mechanisms at once, you can potentially get a stronger anti-tumor immune response than either drug achieves alone.
This is not purely theoretical. In a study using patient-derived xenograft models of nasopharyngeal carcinoma, the combination of cusatuzumab (anti-CD70) and an anti-PD-1 antibody produced the strongest tumor inhibition of any treatment arm. The combination decreased Tregs infiltrating the tumor while simultaneously increasing cytotoxic CD8-positive T cells.5Nature Communications. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction Whether this synergy will translate to meaningful clinical benefit in patients remains to be established in larger trials, but the preclinical results are encouraging enough to have prompted combination studies.
CD70 Beyond Cancer
While most attention has focused on oncology, the CD27-CD70 pathway is also involved in autoimmune disease. When this signaling axis is overactive outside the context of cancer, it can drive excessive immune activation that damages the body’s own tissues. Animal studies have shown that blocking the CD27-CD70 pathway can reduce disease severity in models of rheumatoid arthritis (collagen-induced arthritis) and inflammatory bowel disease (experimental colitis).17PubMed. The CD27-CD70 pathway and pathogenesis of autoimmune disease The connection between aberrant CD70 signaling and autoimmunity has also been studied in conditions like systemic lupus erythematosus and rheumatoid arthritis in humans, though therapeutic targeting in autoimmune disease is still at a much earlier stage than in cancer.
The autoimmune angle also highlights why CD70-targeted cancer drugs need careful safety monitoring. If blocking CD70 can calm an overactive immune system in autoimmune disease, it stands to reason that blocking it in a cancer patient could, at least in theory, impair some normal immune functions. So far the clinical data suggests this is manageable, but it is something that long-term follow-up will need to track.
What Makes CD70 Different from Other Immune Targets
The cancer immunotherapy field is crowded with potential targets, and a reasonable question is why CD70 deserves special attention. A few features set it apart. First, the expression gap between tumor and healthy tissue is unusually large. Most healthy cells do not express CD70 at all, and even immune cells only display it briefly during active immune responses. In contrast, many tumors keep CD70 on their surface continuously. That differential creates a wider therapeutic window than targets like PD-L1, which is expressed in a range of normal tissues.
Second, CD70 sits at a crossroads of multiple immune suppression pathways. It doesn’t just send one signal; it simultaneously drives T cell exhaustion, Treg expansion, and myeloid suppressor cell activation. Blocking it could therefore relieve immunosuppression on multiple fronts at once, rather than addressing just one brake on the immune system.
Third, CD70 is accessible to drugs because it sits on the outside of the cell membrane. This makes it targetable by antibodies, ADCs, CAR-T cells, and bispecific engagers, giving drug developers a wide toolkit to work with. For targets buried inside the cell, the options are much more limited.
The field is still working out which of these therapeutic modalities will ultimately prove most effective for which cancer types. Kidney cancer, with its strong and consistent CD70 overexpression driven by VHL loss, looks like one of the best candidates. Hematologic malignancies like AML and T-cell lymphoma are also being actively pursued, in part because the alternative treatments for relapsed patients in those settings are quite limited. Glioblastoma, while it does express CD70, presents additional challenges related to getting drugs across the blood-brain barrier. The next few years of clinical trial results should start clarifying where CD70-targeted therapies fit into the treatment landscape and whether the promise seen in preclinical work holds up in patients with advanced disease.